| The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC) J Chen, T Kinoshita, T Gururaja, J Sukbuntherng, D James, D Lu, ... European journal of haematology 101 (5), 604-612, 2018 | 46 | 2018 |
| Ibrutinib enhances the activity of anti-CD20 antibodies in an MCL mouse model: effect of drug at clinically relevant concentrations on ADCC and ADCP PP Ng, DK Lu, J Sukbuntherng, JK Neuenburg, DF James, BY Chang Blood 126 (23), 3998, 2015 | 4 | 2015 |
| Novel Irreversible Menin Inhibitor, BMF-219, Shows Potent Single Agent Activity in Clinically Relevant DLBCL Cells P Somanath, D Lu, B Law, TC Archer, A Cacovean, JT Palmer, ... Blood 138, 4318, 2021 | 3 | 2021 |
| 113-LB: Oral Menin Inhibitor, BMF-219, Displays a Significant and Durable Reduction in HbA1c in a Type 2 Diabetes Mellitus Rat Model P Somanath, S Mourya, W Li, TC Archer, B Law, D Lu, T Rughwani, ... Diabetes 71 (Supplement_1), 2022 | 2 | 2022 |
| Bmf-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML B Law, T Rughwani, TC Archer, L Kumar, D Lu, P Somanath, Y Ma, ... Blood 140 (Supplement 1), 6191-6192, 2022 | 1 | 2022 |
| Preclinical activity of irreversible Menin inhibitor, BMF-219, in chronic lymphocytic leukemia. P Somanath, D Lu, B Law, T Archer, T Rughwani, L Kumar, T Kinoshita, ... Journal of Clinical Oncology 40 (16_suppl), 7541-7541, 2022 | 1 | 2022 |
| CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION P Somanath, D LU, T Kinoshita, B Law, T Butler, JT Palmer, N Lin, ... US Patent App. 17/885,213, 2023 | | 2023 |
| Oral Menin Inhibitor, BMF-219, displays a significant and durable reduction in HbA1c in a Type 2 Diabetes Rat Model P Somanath, S Mourya, W Li, T Archer, B Law, D Lu, T Rughwani, ... DIABETOLOGIA 65 (SUPPL 1), S302-S302, 2022 | | 2022 |
| P-107: Anti-tumor activity of covalent menin inhibitor, BMF-219, in high-grade B-cell lymphoma and multiple myeloma preclinical models D Lu, P Somanath, B Law, L Kumar, J Palmer, T Kinoshita, ... Clinical Lymphoma Myeloma and Leukemia 22, S94, 2022 | | 2022 |
| Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors B Law, D Lu, P Somanath, JT Palmer, T Kinoshita, T Butler Cancer Research 82 (12_Supplement), 2665-2665, 2022 | | 2022 |
| Anti-tumor activity of irreversible menin inhibitor, BMF-219, in high-grade B-cell lymphoma and multiple myeloma preclinical models P Somanath, D Lu, B Law, JT Palmer, T Kinoshita, M Balakrishnan, ... Cancer Research 82 (12_Supplement), 2654-2654, 2022 | | 2022 |
| Ibrutinib enhances the anti-tumor efficacy of CTLA-4 blockade in lymphoma and colon cancer models P Ng, D Lu, B Chang Cancer Research 75 (15_Supplement), 259-259, 2015 | | 2015 |
